Yan-Hong Shi

When oncolytic viruses get on CAR: a synergic approach for solid tumor immunotherapy

Chimeric antigen receptor (CAR)-based cell therapies have transformed the treatment of selected hematologic malignancies, yet their efficacy in solid tumors remains limited due to antigen heterogeneity, inadequate trafficking, physical and metabolic barriers, immune suppression, and poor persistence of transferred cell...